Abstract:Background Severe selenium (Se) deficiency, as in Keshan disease, is associated with a fatal form of heart failure (HF), preventable and reversible with Se supplementation. Recent studies have identified Se deficiency as highly prevalent, up to 70%, among patients with HF, and associated with a poorer prognosis. Observational data suggest that Se concentrations <100 μg/L in HF patients and selenoprotein P (SELENOP) concentrations <4.1 mg/L are associated with increased mortality and hospital readmissions. Further, in recent studies, natural autoantibodies (aAb) towards SELENOP have been detected with the potential to disrupt transportation mechanisms. While the evidence does not yet support Se supplementation for HF patients in clinical practice, it does justify the initiation of large, well-designed randomized controlled trials (RCTs). Purpose To assess and confirm the previously reported high prevalence of Se deficiency, measured by both Se and SELENOP concentrations in HF patients and exploring the prevalence of aAb to SELENOP. This will provide a rationale for further, adequately powered and designed, studies of Se supplementation in HF patients. Methods A total of 527 blood samples were obtained from a nationwide Swedish HF biobank, sourced from various hospitals. In those samples; serum Se concentrations in 455 samples using mass spectrometry, SELENOP concentrations in 520 samples using an immunoassay, and prevalence of aAb to SELENOP in 513 samples using an immunoluminometric assay were analyzed. In addition, SELENOP concentrations in 320 HF patients from a Swedish single-center study were analysed. Results The study population had a mean age of 70.3 (±11.8) years (30.5% women). Prevalence of Se deficiency was higher than previously reported. In the national HF registry, the median Se concentration was 75 μg/L and Se concentrations below 100 μg/L were found in 426 (93%) samples. SELENOP concentrations had a median of 3.5 mg/L, corresponding to ~80 μg/L Se, with 80.5% of subjects below SELENOP-concentration of 4.3 mg/L (corresponding to ~100 μg/L Se). In the confirmatory single-center study, the SELENOP median concentration was 3.1 mg/L, corresponding to Se concentrations of ~70 μg/L and SELENOP -concentrations below 4.3 mg/L (corresponding to approximately 100 μg/L Se) were observed in 89.4% of the study population. Further, aAb to SELENOP were prevalent in 9.7% of the population, compared to approximately 1% in healthy subjects. Conclusion This pilot study demonstrates a high prevalence of suboptimal Selenium status in Swedish HF patients which further underscores the need for suitably designed intervention studies to address the efficacy and safety of Se supplementation which can possibly constitute an inexpensive, safe and readily available treatment option for HF patients.

A Multi-Institutional, Retrospective, Observational Study on Administration Status and Safety of In-Hospital Oral Selenium Preparation in Pediatric Patients Predominantly Suffering from Gastrointestinal Disease

Impact of Selenium Deficiency on Clinical Outcomes in Newly Diagnosed Heart Failure Patients in Japan

Selenium in Oncology: From Chemistry to Clinics

A systematic review of Selenium as a complementary treatment in cancer patients

A Plea for Monitoring Serum Selenium Levels in Breast Cancer Patients: Selenium Deficiency Is Rare during the First Year of Therapy, and Selenium Supplementation Is Associated with Elevated Risk of Overdosing

Perioperative selenium administration in cardiac surgery patients, a way out to reduce post surgical adversities? A meta analysis

Effect of High-Dose Selenium on Postoperative Organ Dysfunction and Mortality in Cardiac Surgery Patients: The SUSTAIN CSX Randomized Clinical Trial

Selenium: Dietary Sources, Human Nutritional Requirements and Intake Across Populations

Concurrent quantitative HPLC-mass spectrometry profiling of small selenium species in human serum and urine after ingestion of selenium supplements

Selenium substitution has no direct effect on thyroid hormone metabolism in critically ill patients

Effect of Selenium Supplementation on Lipid Profile, Anemia, and Inflammation Indices in Hemodialysis Patients

REPORT-Parenteral Selenium for the Clinical Effect of Sepsis: A Meta-Analysis of Randomized Controlled Trials.

Developmental Selenium Exposure and Health Risk in Daily Foodstuffs: A Systematic Review and Meta-Analysis

[Two sibling patients with non-Fukuyama type congenital muscular dystrophy with low serum selenium levels--therapeutic effects of oral selenium administration]

Preventative role of Selenium in Keshan Disease: A Review

Varied Doses and Chemical Forms of Selenium Supplementation Differentially Affect Mouse Intestinal Physiology.

Selenium Status and Its Antioxidant Role in Metabolic Diseases

Selenium, selenoprotein P and autoantibodies to selenium transport proteins in Swedish heart failure patients - a pilot study in preparation for a randomized supplementation trial

Investigation of Selenium Nutritional Status and Dietary Pattern among Children in Kashin-Beck Disease Endemic Areas in Shaanxi Province, China using Duplicate Portion Sampling Method

Effect of long-term selenium supplementation on mortality: Results from a multiple-dose, randomised controlled trial

Selenium Intake and Multiple Health-Related Outcomes: an Umbrella Review of Meta-Analyses